Cambridge, MA – Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.
“For decades, our primary treatment option for patients with type 1 diabetes has been the use of insulin to control blood glucose levels, while the underlying autoimmune disease continues to progress,” said Dr. Thomas B. Repas, Clinical Assistant Professor, Department of Internal Medicine, University of South Dakota, Sanford School of Medicine, and an investigator in the DEFEND-2 study. “The future potential of otelixizumab opens up the opportunity for an entirely new treatment approach that can intervene at early onset of type 1 diabetes and potentially break the cycle of the continued progression of this disease that patients manage over their entire lifetime.”
DEFEND-2 is a randomized, placebo-controlled confirmatory Phase 3 trial designed to enroll up to 400 patients, age 12 to 45, with newly diagnosed autoimmune type 1 diabetes. DEFEND-2 is being conducted at more than 200 sites in North America and Europe. Building on DEFEND-1, the DEFEND-2 clinical trial similarly evaluates the efficacy and safety of otelixizumab in an additional study population of patients age 12 to 45 with new-onset type 1 diabetes. In the confirmatory study, otelixizumab is administered as a single course, given not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function that has been endorsed by the U.S. Food and Drug Administration (FDA) at 12 months after dosing. Maintenance of beta cell function has been associated with improved glycemic control (HbA1c levels), fewer hypoglycemic events, fewer hyperglycemic excursions, and a reduction in long-term disease complications in established type 1 diabetes patients, as referenced in the Diabetes Control and Complications Trial (DCCT).
“Tolerx is aggressively moving forward in our clinical development of otelixizumab. We are excited by the potential of this novel drug candidate to change the type 1 diabetes treatment paradigm by inhibiting disease progression and perhaps halting the disease by inducing an immunologic remission,” said Dr. Douglas J. Ringler, President and Chief Executive Officer of Tolerx. “The first patients have been dosed in the DEFEND-2 study, and we believe our study is designed with the robustness and rigor to confirm the efficacy and safety of otelixizumab in a broad patient population.”
For additional information about DEFEND-2, please visit http://www.defendagainstdiabetes.com/.
About Type 1 Diabetes
Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. There are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder involving the body’s immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.
Otelixizumab is a targeted T cell immunomodulator being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells’ ability to make insulin.
Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity. The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline. TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward immune responses. The company also has three pre-clinical candidates, TRX518, TRX585 and TRX385, that enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit http://www.tolerx.com/cms_pr_edit.php?id=174.
The Yates Network
JDRF is a leader in setting the agenda for diabetes research worldwide, and is the largest charitable funder and advocate of type 1 research. The mission of JDRF is to find a cure for diabetes and its complications through the support of research. Type 1 diabetes is a disease which strikes children and adults suddenly and requires multiple injections of insulin daily or a continuous infusion of insulin through a pump. Insulin, however, is not a cure for diabetes, nor does it prevent its eventual and devastating complications which may include kidney failure, blindness, heart disease, stroke, and amputation.
Since its founding in 1970 by parents of children with type 1 diabetes, JDRF has awarded more than $1.4 billion to diabetes research, including more than $100 million last year.